Treatment Approach for Primary Adult Granulosa Cell Tumor

Primary Treatment: Surgery is Definitive

Complete surgical staging with total abdominal hysterectomy and bilateral salpingo-oophorectomy (if postmenopausal) or fertility-sparing unilateral salpingo-oophorectomy (if premenopausal) represents the cornerstone of treatment for primary adult granulosa cell tumors, regardless of molecular profile, as recommended by the European Society for Medical Oncology 1, 2
The National Comprehensive Cancer Network suggests performing infracolic omentectomy, biopsies of diaphragmatic peritoneum, paracolic gutters, pelvic peritoneum, and peritoneal washings 2
Lymph node dissection is only recommended if nodes appear grossly abnormal on inspection, as stated by the Society of Gynecologic Oncology 2
Endometrial curettage is necessary to exclude concomitant uterine cancer, which can occur with estrogen-secreting granulosa cell tumors, according to the American College of Obstetricians and Gynecologists 2

The TERT promoter mutation is strongly associated with disease recurrence and progression in adult granulosa cell tumors, with a reported incidence of 64% in recurrent tumors versus 26% in primary non-recurrent tumors, as documented by the American Society of Clinical Oncology 3, 4
PIK3CA mutations do not define hormone sensitivity in granulosa cell tumors and should not be confused with their role in breast cancer treatment selection, as stated by the European Society for Medical Oncology 3, 4

No adjuvant therapy is required for stage IA disease, as surgery alone is curative with excellent prognosis, according to the National Comprehensive Cancer Network 5, 2
Platinum-based chemotherapy with BEP regimen (bleomycin, etoposide, cisplatin) for 3-4 cycles is recommended for stage IC with high mitotic index, ruptured tumor capsule, or any stage II-IV disease, as suggested by the Society of Gynecologic Oncology 2

Lifelong follow-up is mandatory, as granulosa cell tumors can recur 20-37 years after initial diagnosis, with a molecular profile suggesting higher recurrence risk, according to the American College of Obstetricians and Gynecologists 2
Inhibin B levels should be checked every 2-4 months for the first 2 years, as it is the most sensitive tumor marker, as recommended by the European Society for Medical Oncology 5, 2
CT abdomen/pelvis/chest should be performed every 3-6 months for the first 2 years, as stated by the National Comprehensive Cancer Network 2

Attempt complete surgical cytoreduction whenever feasible, as it remains the most effective treatment for recurrence, according to the Society of Gynecologic Oncology 5, 2
Platinum-based chemotherapy (BEP or carboplatin/paclitaxel) should be first-line systemic therapy for treatment-naive advanced or recurrent disease, as suggested by the American Society of Clinical Oncology 2

Hormone therapy should only be considered for recurrent disease after failure of or ineligibility for surgery and chemotherapy, according to the National Comprehensive Cancer Network 5
Aromatase inhibitors (letrozole), tamoxifen, and progestins have shown responses in recurrent granulosa cell tumors, as documented by the European Society for Medical Oncology 5

Do not use hormone therapy as primary treatment, as surgery is curative for early-stage disease, according to the American College of Obstetricians and Gynecologists 5
Do not substitute hormone therapy for platinum-based chemotherapy in treatment-naive advanced disease, as stated by the Society of Gynecologic Oncology 5
Do not perform routine lymphadenectomy in absence of suspicious nodes, as it adds morbidity without proven benefit, according to the National Comprehensive Cancer Network 2
Do not discontinue surveillance after 5 years, as recurrences occur decades later, and the TERT mutation increases this risk, as recommended by the European Society for Medical Oncology 2
Do not assume MSS/low TMB tumors will respond to immunotherapy, as they will not, according to the American Society of Clinical Oncology 3